Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Exxon Mobil Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Published 02/02/2024, 07:10
Updated 02/02/2024, 08:40
© Reuters. Exxon Mobil Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Exxon Mobil Corporation (NYSE: XOM) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 2, 2024.

Analysts expect the company to report quarterly earnings at $2.21 per share, down from year-ago earnings of $3.4 per share. The company is projected to post revenue of $85.23 billion for the latest quarter, compared to $95.43 billion in the year-earlier quarter, according to data from Benzinga Pro.

In a surprising move, Exxon Mobil has recently taken legal action against its investors. The company is seeking to block a climate proposal from being voted on at its upcoming shareholder meeting.

Exxon Mobil shares fell 0.4% to close at $102.39 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • UBS analyst Jon Rigby maintained a Buy rating and cut the price target from $133 to $132 on Jan. 23, 2024. This analyst has an accuracy rate of 62%.
  • TD Cowen analyst Jason Gabelman upgraded the stock from Market Perform to Outperform with a price target of $115 on Jan. 23, 2024. This analyst has an accuracy rate of 71%.
  • Redburn Atlantic analyst Peter Low upgraded the stock from Neutral to Buy and raised the price target from $116 to $119 on Jan. 9, 2024. This analyst has an accuracy rate of 72%.
  • Erste Group analyst Hans Engel downgraded the stock from Buy to Hold on Dec. 22, 2023. This analyst has an accuracy rate of 70%.
  • JP Morgan analyst John Royall maintained an Overweight rating and cut the price target from $134 to $127 on Dec. 8, 2023. This analyst has an accuracy rate of 70%.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read This Next: Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

Latest Ratings for XOM

Mar 2022Wells FargoMaintainsOverweight
Mar 2022MKM PartnersMaintainsBuy
Mar 2022BMO CapitalMaintainsMarket Perform

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.